{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:05:43Z","timestamp":1790676343805,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.04.089","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T07:36:33Z","timestamp":1652772993000},"page":"3588-3596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8\u00a0years of age: A phase 2 randomized, double-blind study"],"prefix":"10.1016","volume":"40","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Saez-Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vezna","family":"Blazevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pio","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisei","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Mendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-4208","authenticated-orcid":false,"given":"James","family":"Sherwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Baehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.04.089_b0005","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3201\/eid1408.071114","article-title":"Systematic literature review of role of noroviruses in sporadic gastroenteritis","volume":"14","author":"Patel","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.089_b0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcv.2012.11.011","article-title":"Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: Global distribution of genogroups, genotypes and GII.4 variants","volume":"56","author":"Hoa Tran","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2022.04.089_b0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3109\/00365548.2011.588610","article-title":"Noroviruses as a major cause of acute gastroenteritis in Finland, 2009\u20132010","volume":"43","author":"Puustinen","year":"2011","journal-title":"Scand J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.089_b0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMsa1206589","article-title":"Norovirus and medically attended gastroenteritis in U.S. children","volume":"368","author":"Payne","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.089_b0025","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.vaccine.2020.01.098","article-title":"Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus","volume":"38","author":"K\u00f5ivum\u00e4gi","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.089_b0030","unstructured":"Halasa N, Piya B, Stewart LS, Rahman H, Payne DC, Woron A, et al. The changing landscape of pediatric viral enteropathogens in the post-rotavirus vaccine era. Clin Infect Dis 2020 Feb 3. pii: ciaa100."},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.089_b0035","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S1473-3099(20)30058-X","article-title":"Community burden and transmission of acute gastroenteritis caused by norovirus and rotavirus in the Netherlands (RotaFam): a prospective household-based cohort study","volume":"20","author":"Quee","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.089_b0040","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/infdis\/jiu337","article-title":"A novel intramuscular bivalent norovirus virus-like particle vaccine candidate\u2013reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults","volume":"210","author":"Treanor","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.089_b0045","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jiw259","article-title":"Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized controlled trial","volume":"214","author":"Atmar","year":"2016","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.089_b0050","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/infdis\/jix572","article-title":"Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial","volume":"217","author":"Leroux-Roels","year":"2018","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.089_b0055","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/infdis\/jiz170","article-title":"Persistence of antibodies to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: 1-year follow-up with memory probe vaccination","volume":"220","author":"Atmar","year":"2019","journal-title":"J Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2022.04.089_b0060","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1016\/j.vaccine.2012.03.050","article-title":"Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations","volume":"30","author":"Parra","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.089_b0065","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/CVI.00196-15","article-title":"Serological correlates of protection against a GII.4 norovirus","volume":"22","author":"Atmar","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.089_b0070","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1086\/656364","article-title":"Serological correlate of protection against Norovirus-induced gastroenteritis","volume":"202","author":"Reeck","year":"2010","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.089_b0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(14)70767-4","article-title":"Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis","volume":"14","author":"Ahmed","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.089_b0080","doi-asserted-by":"crossref","first-page":"e0142927","DOI":"10.1371\/journal.pone.0142927","article-title":"Aetiology-specific estimates of the global and regional incidence and mortality of diarrhoeal diseases commonly transmitted through food","volume":"10","author":"Pires","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.089_b0085","article-title":"Preadaptation of pandemic GII.4 noroviruses in unsampled virus reservoirs years before emergence. Virus","volume":"6","author":"Ruis","year":"2020","journal-title":"Evolution"},{"key":"10.1016\/j.vaccine.2022.04.089_b0090","doi-asserted-by":"crossref","unstructured":"Huhti L, Blazevic V, Puustinen L, Hemming M, Salminen M, Vesikari T. Genetic analyses of norovirus GII.4 variants in Finnish children from 1998 to 2013. Infect Genet Evol 2014;26:65\u201371.","DOI":"10.1016\/j.meegid.2014.05.003"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.089_b0095","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3390\/microorganisms8121873","article-title":"Differences in illness severity among circulating norovirus genotypes in a large pediatric cohort with acute gastroenteritis","volume":"8","author":"Bhavanam","year":"2020","journal-title":"Microorganisms"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.089_b0100","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/infdis\/jiu497","article-title":"Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults","volume":"211","author":"Bernstein","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.089_b0105","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2020.01383","article-title":"Norovirus vaccines: Priorities for future research and development","volume":"11","author":"Esposito","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.04.089_b0110","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/infdis\/jiaa292","article-title":"The clinical and economic burden of norovirus gastroenteritis in the United States","volume":"222","author":"Bartsch","year":"2020","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.089_b0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.amepre.2020.10.022","article-title":"Potential clinical and economic value of norovirus vaccination in the community setting","volume":"60","author":"Bartsch","year":"2021","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2022.04.089_b0120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5644\/ama2006-124.317","article-title":"Norovirus infections dDrop 49% in the United States with strict COVID-19 public health interventions","volume":"49","author":"Lennon","year":"2020","journal-title":"Acta Med Acad"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.089_b0125","doi-asserted-by":"crossref","first-page":"e0256638","DOI":"10.1371\/journal.pone.0256638","article-title":"Differential impact of the COVID-19 pandemic on laboratory reporting of Norovirus and campylobacter in England: a modelling approach","volume":"16","author":"Ondrikova","year":"2021","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.089_b0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2021.02.012","article-title":"Decrease in Norovirus infections in Germany following COVID-19 containment measures","volume":"82","author":"Eigner","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2022.04.089_b0135","doi-asserted-by":"crossref","DOI":"10.33321\/cdi.2021.45.5","article-title":"Decreased incidence of Enterovirus and Norovirus infections during the COVID-19 pandemic, Victoria, Australia, 2020","volume":"45","author":"Bruggink","year":"2021","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.vaccine.2022.04.089_b0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/infdis\/jiab093","article-title":"Impact of nonpharmaceutical interventions for Severe Acute Respiratory Syndrome Coronavirus 2 on Norovirus outbreaks: an analysis of outbreaks reported by 9 US states","volume":"224","author":"Kraay","year":"2021","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.089_b0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02153-8","article-title":"Predicted Norovirus resurgence in 2021\u20132022 due to the relaxation of nonpharmaceutical interventions associated with COVID-19 restrictions in England: a mathematical modeling study","volume":"19","author":"O\u2019Reilly","year":"2021","journal-title":"BMC Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:12:25Z","timestamp":1759403545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":29,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22005503"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.089","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8\u00a0years of age: A phase 2 randomized, double-blind study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}